CYP2A13 Antibody

Code CSB-PA001946
Size US$100
Order now
Image
  • Western Blot analysis of A549 cells using CYP2A13 Polyclonal Antibody
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
CYP2A13
Alternative Names
CP2AD_HUMAN antibody; CPAD antibody; CYP2A antibody; CYP2A13 antibody; CYPIIA13 antibody; Cytochrome P450 2A13 antibody; Cytochrome P450 family 2 subfamily A member 13 antibody; CYTOCHROME P450; SUBFAMILY IIA; POLYPEPTIDE 13 antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Synthesized peptide derived from the Internal region of Human CYP2A13.
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Isotype
IgG
Purification Method
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Form
Liquid
Tested Applications
WB, IHC, IF, ELISA
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:2000
IHC 1:100-1:300
IF 1:200-1:1000
ELISA 1:20000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Exhibits a coumarin 7-hydroxylase activity. Active in the metabolic activation of hexamethylphosphoramide, N,N-dimethylaniline, 2'-methoxyacetophenone, N-nitrosomethylphenylamine, and the tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Possesses phenacetin O-deethylation activity.
Gene References into Functions
  1. CYP2A13 is the most efficient enzyme to metabolize N'-Nitrosonornicotine in vitro. PMID: 27567546
  2. The results of this case-control study suggested that the CYP2A13*1/*2 genotype decreased the risk of susceptibility to bladder cancer in Japanese smokers PMID: 27725446
  3. CYP2A13 levels in human lungs can be suppressed by disease-associated inflammation in tissue donors. PMID: 25710941
  4. an etiologically relevant interaction between CYP2A13 and ABCB1 associated with lung cancer was analysed PMID: 25667220
  5. The transgenic CYP2A13 is active. PMID: 24907355
  6. CYP2A13 played a critical role in AFB1-induced neoplastic transformation. PMID: 24114584
  7. Data suggest important role of CYP2A13 in AFG1- (aflatoxin G1)-induced cytotoxicity, DNA damage, and activation of signal pathways in bronchial epithelium; data suggest similarities in CYP2A13-catalyzed bioactivation of AFG1 and AFB1 (aflatoxin B1). PMID: 23907605
  8. CYP2A13 is efficient in 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone bioactivation in vivo and it can mediate 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis. PMID: 23917075
  9. Findings suggest the potential involvement of pulmonary CYP2A13 in the early occurrence of NSCLC as well as in the development of EGFR gene mutations. PMID: 23752126
  10. an efficient approach for expressing functionally characterized, highly active and homogeneous CYP2A13 proteins. PMID: 23463547
  11. CYP2A13 plays an important role in low-concentration AFB1-induced DNA damage, possibly linking environmental airborne AFB1 to genetic injury in the human respiratory system. PMID: 23583631
  12. Findings suggest that CYP2A13 plays an important role in low-concentration AFB1-induced DNA damage, possibly linking environmental airborne AFB1 to genetic injury in human respiratory system. PMID: 23602888
  13. The differential distribution pattern of CYP2A13 in the respiratory tract, which is of importance in considering the pulmonary susceptibility to carcinogens and the following lung cancer development, is detailed. PMID: 22890016
  14. Tissue distribution of transgenic mRNA expression agrees well with the known respiratory tract-selective expression of CYP2A13 and CYP2F1 and hepatic expression of CYP2B6 in humans. PMID: 22397853
  15. Report selective expression of CYP2A13 in human pancreatic alpha-islet cells. PMID: 22798551
  16. Although both the hepatic CYP2A6 and respiratory CYP2A13 enzymes metabolize these compounds, CYP2A13 does so with much higher catalytic efficiency, but the structural basis for this has been unclear PMID: 22700965
  17. The distribution frequencies of all eight known CYP2A13 missense alleles were examined in a Chinese Han population. PMID: 22315333
  18. present results provide the first direct in vitro evidence demonstrating the predominant roles of CYP2A13 in 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced mutagenesis, possibly via metabolic activation of NNK alpha-hydroxylation PMID: 21473878
  19. single nucleotide polymorphisms within the CYP2A13 gene affect metabolism of 5-methoxypsoralen in humans. PMID: 20798279
  20. 2 novel polymorphisms T478C and T494C in CYP2A13 gene were associated with significantly reduced risk of cancer. CYP2A13 haplotype carrying variant alleles of T478C/T494C found associated with reduced risk of head/neck cancer. PMID: 20534012
  21. significant interaction between smoking and methylation status of CYP2A13 in head and neck cancer. PMID: 20846153
  22. The mechanisms underlying the decreased allelic expression of a common CYP2A13 allele (7520C>G) in the human lung, were investigated. PMID: 20431511
  23. Observed clear prevalence of the variant CYP2A13 alelle causing premature stop at codon 101 (knockout allele *7) among the controls in comparison with the pancreatic cancer patients. PMID: 19812523
  24. genetic polymorphism: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant PMID: 12130698
  25. CYP2A13 allele is associated with reduced risk of lung adenocarcinoma, suggesting the role of NNK-CYP2A13 interaction as a causative factor for the cancer. PMID: 14633739
  26. In order to investigate the extent of CYP2A13 genetic polymorphism in a French Caucasian population of 102 individuals, a screening for sequence variations in the 5'-untranslated and protein encoding regions of its gene was performed. PMID: 15063809
  27. The CYP2A13 Arg257Cys variant represents a common polymorphism in Chinese, with the 257Cys allele frequency being similar to the Hispanic and Asian groups, but significantly lower than in blacks PMID: 15115698
  28. CYP2A13 mutant proteins showed a significant decrease in the catalytic efficiency for NNK alpha-hydroxylation PMID: 15333516
  29. structure of CYP2A13 was determined to 2.35A by x-ray crystallography and compared with structures of CYP2A6. PMID: 17428784
  30. the reported association of the CYP2A13(*)2 allele with decreased incidences of lung adenocarcinoma in smokers can be at least partly explained by a decrease in CYP2A13 function PMID: 18669584

Show More

Hide All

Subcellular Location
Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein.
Protein Families
Cytochrome P450 family
Tissue Specificity
Expressed in liver and a number of extrahepatic tissues, including nasal mucosa, lung, trachea, brain, mammary gland, prostate, testis, and uterus, but not in heart, kidney, bone marrow, colon, small intestine, spleen, stomach, thymus, or skeletal muscle.
Database Links

HGNC: 2608

OMIM: 608055

KEGG: hsa:1553

STRING: 9606.ENSP00000332679

UniGene: Hs.567252

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*